Shenzhen Uni-Medica Technology (深圳联合医学科技)

Shen Zhen Shi, China

Shenzhen Uni-medica Technology Co., Ltd (Uni-medica) is a national high-tech enterprise. It has established cooperation and jointly performed a number of scientific research projects with the Hong Kong University of Science and Technology, Shenzhen University and Chinese Academy of Sciences. Uni-medica was also selected as one of the top 100 new Chinese innovative enterprises.The company takes the technical innovation of molecular detection methods as the core driving force, and focuses on the Rï¼†D and industrialization of molecular diagnostic products aiming at prevention and control of infectious diseases and genetic diseases. Uni-medica provides total solution of accurate diagnosis of infectious diseases and genetic diseases based on multi-omics technologies, including multiplex PCR, NGS technology and flow cytometry. Uni-medica is qualified by ISO 13485 and CFDA quality control system. The pathogen molecular detection products are daily used in hundreds of hospitals, Centers for Disease Control and Prevention and Quarantine Laboratories throughout the country, providing strong support for prevention and control of infectious diseases.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Shenzhen Uni-Medica Technology (深圳联合医学科技) on @MedStartr Today #InfectiousDiseases #GeneticDisorders #InfectiousDisease #MedMo #MedStartrVentures

https://www.medstartr.ai/s/GryiYEoy-TU

Get Involved in Shenzhen Uni-Medica Technology (深圳联合医学科技)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2011
Website: uni-medica.com/

Disease Areas

Infectious Diseases Genetic Disorders

Technologies

Multi-OmicsNext-Generation SequencingPCRFlow Cytometry

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Shenzhen Uni-Medica Technology (深圳联合医学科技)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.